Durvalumab + Oleclumab
Phase 2Withdrawn 1 views this week 0 watching💤 Quiet
Interest: 27/100
27
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pancreatic Ductal Adenocarcinoma
Conditions
Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck
Trial Timeline
Jan 1, 2021 → Jan 1, 2023
NCT ID
NCT04262388About Durvalumab + Oleclumab
Durvalumab + Oleclumab is a phase 2 stage product being developed by AstraZeneca for Pancreatic Ductal Adenocarcinoma. The current trial status is withdrawn. This product is registered under clinical trial identifier NCT04262388. Target conditions include Pancreatic Ductal Adenocarcinoma, Non-small Cell Lung Cancer, Squamous Cell Carcinoma of Head and Neck.
What happened to similar drugs?
9 of 20 similar drugs in Pancreatic Ductal Adenocarcinoma were approved
Approved (9) Terminated (4) Active (11)
Hype Score Breakdown
Clinical
12
Activity
0
Company
15
Novelty
0
Community
0
Clinical Trials (4)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04262375 | Phase 2 | Withdrawn |
| NCT04262388 | Phase 2 | Withdrawn |
| NCT03875573 | Phase 2 | Active |
| NCT03773666 | Phase 1 | Completed |
Competing Products
20 competing products in Pancreatic Ductal Adenocarcinoma